Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration

Ferrara, 2004, Vascular endothelial growth factor, Endocr Rev, 25, 581, 10.1210/er.2003-0027

Adamis, 2005, The role of vascular endothelial growth factor in ocular health and disease, Retina, 25, 111, 10.1097/00006982-200502000-00001

Holz, 2004, Pathogenesis of lesions in late age-related macular disease, Am J Ophthalmol, 137, 504, 10.1016/j.ajo.2003.11.026

Krzystolik, 2002, Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment, Arch Ophthalmol, 120, 338, 10.1001/archopht.120.3.338

Gragoudas, 2004, Pegaptanib for neovascular age-related macular degeneration, N Engl J Med, 351, 2805, 10.1056/NEJMoa042760

2005, Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium, Retina, 25, 815, 10.1097/00006982-200510000-00001

van Wijngaarden, 2005, Inhibitors of ocular neovascularization, JAMA, 293, 1509, 10.1001/jama.293.12.1509

2001, Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin, Arch Ophthalmol, 119, 198

2003, Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin, Arch Ophthalmol, 121, 1253, 10.1001/archopht.121.9.1253

Hurwitz, 2004, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med, 350, 2335, 10.1056/NEJMoa032691

Rosenfeld, 2005, Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration, Ophthalmology, 112, 1048, 10.1016/j.ophtha.2005.01.043

Gaudreault, 2005, Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration, Invest Ophthalmol Vis Sci, 46, 726, 10.1167/iovs.04-0601

Mordenti, 1999, Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration, Toxicol Pathol, 27, 536, 10.1177/019262339902700507

Michels, 2005, Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration, Ophthalmology, 112, 1035, 10.1016/j.ophtha.2005.02.007

Rosenfeld, 2005, Optical coherence tomography findings after intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration, Ophthalmic Surg Lasers Imaging, 36, 331, 10.3928/1542-8877-20050701-14

Nguyen, 2005, Bevacizumab suppresses choroidal neovascularization caused by pathological myopia [letter], Br J Ophthalmol, 89, 1368, 10.1136/bjo.2005.066431

FDA Medwatch. Barron H, Genentech. Important drug warning [letter]. Available at: http://www.fda.gov/medwatch/SAFETY/2005/Avastin_dearhcp.pdf. Accessed October 10, 2005.

Schachat, 2003, Safe and effective, Ophthalmology, 110, 2073, 10.1016/S0161-6420(03)01004-2

Yourey, 2000, Vascular endothelial cell growth factors promote the in vitro development of rat photoreceptor cells, J Neurosci, 20, 6781, 10.1523/JNEUROSCI.20-18-06781.2000

Kim, 1999, Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes, Invest Ophthalmol Vis Sci, 40, 2115

Rosenfeld, 2005, Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion, Ophthalmic Surg Lasers Imaging, 36, 336, 10.3928/1542-8877-20050701-15

Han, 2004, Intravitreal human immune globulin in a rabbit model of Staphylococcus aureus toxin-mediated endophthalmitis, Trans Am Ophthalmol Soc, 102, 305

Green, 1996, Vol. 2, 673

Green, 2001, Vitreoretinal interface, Vol. 3, 1886

Hogan, 1971, 497

Matsumoto, 1984, Topographic variations in the rabbit and primate internal limiting membrane, Invest Ophthalmol Vis Sci, 25, 71

Jackson, 2003, Human retinal molecular weight exclusion limit and estimate of species variation, Invest Ophthalmol Vis Sci, 44, 2141, 10.1167/iovs.02-1027

Hogan, 1971, 491

Kimura, 1994, Removal of subretinal hemorrhage facilitated by preoperative intravitreal tissue plasminogen activator [letter], Retina, 14, 83, 10.1097/00006982-199401000-00018

Kamei, 1999, A study of the ability of tissue plasminogen activator to diffuse into the subretinal space after intravitreal injection in rabbits, Am J Ophthalmol, 128, 739, 10.1016/S0002-9394(99)00239-1

Johnson, 2000, Pneumatic displacement of submacular hemorrhage, Curr Opin Ophthalmol, 11, 201, 10.1097/00055735-200006000-00009

Genentech. Genentech announces plans to file for FDA approval of Lucentis for the treatment of wet age-related macular degeneration in December [press release, September 7, 2005]. Available at: http://www.gene.com/gene/news/press-releases/display.do?method=detail&id=8827&categoryid=3. Accessed November 12, 2005.

Reichel, 2005, Intravitreal bevacizumab for choroidal neovascularization and cystoid macular edema, Ophthalmic Surg Lasers Imaging, 36, 270, 10.3928/1542-8877-20050701-03